![Andrew Scharenberg](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Andrew Scharenberg
Chief Executive Officer at Umoja Biopharma, Inc.
Andrew Scharenberg active positions
Companies | Position | Start | End |
---|---|---|---|
Umoja Biopharma, Inc.
![]() Umoja Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Umoja Biopharma, Inc. engages in the development of immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. It offers an integrated cellular immunotherapy platform comprising VivoVec in vivo delivery, RACR/CAR synthetic receptor payload and TumorTag targeting technologies that attack cancer cells. The company was founded by Michael Jensen, Philip Low, Andy Scharenberg and Ryan Crisman and is headquartered in Seattle, WA. | Chief Executive Officer | - | - |
Founder | - | - | |
Director/Board Member | - | 10/05/2022 | |
Chairman | 10/05/2022 | 16/11/2022 | |
MPM BioImpact, Inc
![]() MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 31/05/2019 | - |
Career history of Andrew Scharenberg
Former positions of Andrew Scharenberg
Companies | Position | Start | End |
---|---|---|---|
Casebia Therapeutics LLC
![]() Casebia Therapeutics LLC Pharmaceuticals: GenericHealth Technology Casebia Therapeutics LLC discovers, develops, and commercializes gene-editing therapeutics to treat the genetic causes of bleeding disorders and autoimmune disease. The joint venture company is based in Cambridge, MA. | Corporate Officer/Principal | 30/06/2017 | 31/07/2019 |
BLUEBIRD BIO, INC. | Consultant / Advisor | 30/06/2014 | 31/05/2017 |
Cellectis, Inc.
![]() Cellectis, Inc. Pharmaceuticals: MajorHealth Technology Part of Cellectis SA, Cellectis, Inc. engages in the upstream research of genome engineering and in the development of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers. The company is based in New York, NY. André Choulika has been the CEO of the company since 2014. | Corporate Officer/Principal | 30/06/2011 | 29/06/2014 |
GENERATION BIO CO. | Founder | 28/02/2017 | - |
Training of Andrew Scharenberg
UNC School of Medicine | Graduate Degree |
Statistics
International
United States | 8 |
Operational
Founder | 2 |
Corporate Officer/Principal | 2 |
Director/Board Member | 1 |
Sectoral
Health Technology | 6 |
Finance | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
BLUEBIRD BIO, INC. | Health Technology |
GENERATION BIO CO. | Health Technology |
Private companies | 4 |
---|---|
MPM BioImpact, Inc
![]() MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
Cellectis, Inc.
![]() Cellectis, Inc. Pharmaceuticals: MajorHealth Technology Part of Cellectis SA, Cellectis, Inc. engages in the upstream research of genome engineering and in the development of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers. The company is based in New York, NY. André Choulika has been the CEO of the company since 2014. | Health Technology |
Casebia Therapeutics LLC
![]() Casebia Therapeutics LLC Pharmaceuticals: GenericHealth Technology Casebia Therapeutics LLC discovers, develops, and commercializes gene-editing therapeutics to treat the genetic causes of bleeding disorders and autoimmune disease. The joint venture company is based in Cambridge, MA. | Health Technology |
Umoja Biopharma, Inc.
![]() Umoja Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Umoja Biopharma, Inc. engages in the development of immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. It offers an integrated cellular immunotherapy platform comprising VivoVec in vivo delivery, RACR/CAR synthetic receptor payload and TumorTag targeting technologies that attack cancer cells. The company was founded by Michael Jensen, Philip Low, Andy Scharenberg and Ryan Crisman and is headquartered in Seattle, WA. | Health Technology |
- Stock Market
- Insiders
- Andrew Scharenberg
- Experience